Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 6,275 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Steroid Clear all

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: Lateral Epicondylitis
Interventions: Not listed
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions: CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more

Conditions: Pseudophakia, Inflammation
Interventions: loteprednol 0.5% ophthalmic solution; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Independence, Missouri

Conditions: Gender Dysphoria
Interventions: 17beta Estradiol; Drug
Lead sponsor: MaineHealth; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dexamethasone, gabapentin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 247
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 163 more

Conditions: Cystic Fibrosis, Dysbiosis
Interventions: Vitamin D3, Placebo vitamin D3, Inulin, Placebo Inulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colorectal Cancer
Interventions: Vitamin D3 (cholecalciferol), Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: RPS19 Deficient Diamond-Blackfan Anemia
Interventions: APR-2020; Biological
Lead sponsor: Apriligen, Inc.; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more

Conditions: AL Amyloidosis
Interventions: Venetoclax, Dexamethasone; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervicogenic Upper Extremity Radiculopathy
Interventions: dexamethasone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: Fulvestrant, MLN9708; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Carpal Tunnel Syndrome
Interventions: Fat Injection, Steroid Injection; Other · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Degeneration, Retinal Vein Occlusion
Interventions: Triamcinolone Acetonide (TAC-PF); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thymoma and Thymic Carcinoma
Interventions: octreotide acetate, prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 24
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Advanced Solid Tumors, Malignant Neoplasm
Interventions: MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Community Acquired Respiratory Disease Syndrome
Interventions: Inactive Substance, Methylprednisolone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more

Conditions: Esophageal Stricture
Interventions: Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Polycystic Ovarian Syndrome, Infertility
Interventions: Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more

Conditions: Menopause, Aging, Blood Pressure
Interventions: Transdermal estradiol, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Kidney Transplantation, Graft Rejection
Interventions: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Search by objective public record fields.

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Comparison of Intra-articular and Intra-tendinous Injections for Treatment of Lateral Epicondylitis

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients

Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

Efficacy of Vitamin D in Colorectal Cancer Chemoprevention

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Transforaminal Versus Lateralized Interlaminar Cervical Epidurals

Phase I Study of the Combination of MLN9708 and Fulvestrant

Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)

Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)